Introduction: B. myrtifolia and S. anisatum are native Australian trees with uses as traditional medicines and bushfoods. Essential oils produced from leaves of these species have reputed antiseptic properties. Despite this, B. myrtifolia and S. anisatum leaf solvent extractions have not been rigorously examined for antibacterial properties against many pathogens. Methods: The antimicrobial activity of aqueous and methanolic leaf extracts of B. myrtifolia and S. anisatum was investigated by disc diffusion and growth time course assays against a panel of pathogenic bacteria. The growth inhibitory activity was quantified by MIC determination. Toxicity was determined using the Artemia franciscana nauplii bioassay. Results: Methanolic and aqueous B. myrtifolia and S. anisatum leaf extracts inhibited the growth of a wide range of bacterial species. Growth of both gram positive and gram negative bacteria was inhibited the B. myrtifolia and S. anisatum extracts to approximately the same extent. In general, S. anisatum extracts were more potent inhibitors of bacterial growth than were the B. myrtifolia extracts, and (with some noteable exceptions) the methanolic extracts were generally more potent than the aqueous extracts. The B. myrtifolia and S. anisatum extracts were particularly potent inhibitors of P. mirabilis growth, with MIC values as low as 105 µg/mL (aqueous S. anisatum extract). The antibacterial activity of the methanolic B. myrtifolia and S. anisatum extracts were further investigated by growth time course assays which showed significant growth inhibition in cultures of E. coli, K. pneumpniae and P. mirabilis within 1 h of exposure. All extracts were determined to be nontoxic in the Artemia franciscana nauplii bioassay, indicating their safety for internal use as well as for topical uses. Conclusions: The lack of toxicity of the B. myrtifolia and S. anisatum extracts and their growth inhibitory bioactivity against a panel of pathogenic bacteria partially validate Australian Aboriginal usage of these species as antiseptic agent and indicate their potential in the development of antiseptic agents.
INTRODUCTION
The therapeutic potential of the aromatic flora of Australia has been recognised for many thousands of years. The first Australians had welldeveloped ethnopharmacological systems and understood the therapeutic properties of a wide variety of aromatic Australian plants. 1 More recently, Sir Joseph Banks (the botanist aboard Captain James Cook's voyage of the Endeavour) coined the phrase tea tree' for the endemic Australian plant Melaleuca alternifolia due to similarities in use with Camellia sinensis, and some of its perceived therapeutic properties. 1 Nowadays, a thriving trade exists, with 'Tea Tree' essential oils marketed globally. Similarly, the therapeutic properties of Eucalyptus spp. are well documented. 2, 3 Plants of the genus Eucalyptus are now recognised for their potent antimicrobial activities and are commonly used as topical antiseptics. More recently, the bacterial growth inhibitory properties of many genera within the family Myrtaceae have been documented. In particular, Callistemon spp., 4 Eugenia spp., 1 Kunzea spp., 1, 5 Leptospermum 1 and Syzygium spp. [6] [7] [8] have been reported to inhibit the growth of a wide panel of bacteria, including many medicinally important pathogens. Despite this, the antibacterial properties of several Myrtaceae are yet to be rigorously examined. Backhousia myrtifolia Hook. & Harv. (Figure 1a ) is a medium tree which is native to subtropical rainforest areas of eastern Australia. The leaves of this plant are dried to produce 'cinnamon myrtle' , which is used as an herb and food flavouring. 9 Studies in our laboratory 10 and elsewhere 11, 12 have demonstrated the antibacterial activity of leaves of the taxonomically related species Backhousia citriodora F. Muell. (commonly known as lemon myrtle). Interestingly, no reports of Aboriginal medicinal use of either B. citriodora or B. myrtifolia were found in the literature, although the leaves of both species were used in cooking. Most of the studies of Backhousia spp. antibacterial potential focus on the essential oil of the leaves. 11, 12 In most plants of this genus, the levels and composition of the essential oil terpenoid components receives the most interest. In particular, the monoterpenoid composition of Backhousia spp. has been extensively reported. B. citriodora essential oils contain more than 90% citral, which comprises a mixture of neral (α-citral; Figure 1c ) and geranial (β-citral; Figure 1d ). 13 Both neral and geranial have been previously reported to have potent antibacterial activity against a variety of bacteria. 11, 14, 15 Similarly, the high monoterpenoid composition of B. myrtifolia essential oils is known, with methyl eugenol ( Figure 1e ) and elemicin ( Figure 1f ) recognised as the major components. The antiseptic properties of these compounds is also well established. 16 Syzygium anisatum (Vickery) Craven & Biffen (Figure 1b ; formerly Backhousia anisata; commonly known as anise myrtle) is a related species which has a similar but limited occurrence in eastern Australian subtropical rainforests. 1 As for Backhousia spp., S. anisatum is used as a bushfood spice and the leaves are distilled for the essential oil, which is rich in anethole (anise camphor; Figure 1g ) and chavicol (Figure 1h ). Anethole and chavicol have potent bactericidal activity, with minimum bactericidal activities (MBC) as low as 100 µg/mL. 17 Despite this, studies into the antibacterial properties of S. anisatum extracts towards many bacterial pathogens are lacking.
Most of the studies reporting antibacterial properties for Backhousia spp. and Syzygium spp. have examined essential oils. The use of essential oils for the testing of antimicrobial activity can be problematic. The relative insolubility of many of the oil components retards their diffusion through agar gels in agar dilution or disc diffusion studies. Many studies have utilised solubilising agents (eg. Tween 80) to aid oil component diffusion, resulting in variable results. 18, 19 Solubilising agents appear to increase the susceptibility of some bacteria to antimicrobial agents, decrease the susceptibility of others, whilst having no effect on yet other bacteria. Recent studies have reported the antibacterial activity of methanolic extracts of B. citriodora leaves against a panel of bacteria. 10 The current report was undertaken to extend those studies to examine 2 taxonomically related Myrtaceae spp. (B. myrtifolia and S. anisatum) for similar growth inhibitory properties against a panel of pathogenic bacteria.
MATERIALS AND METHODS

Plant collection and extraction
Backhousia myrtifolia Hook. & Harv. and Syzygium anisatum (Vickery) Craven & Biffen leaves were obtained from and identified by Philip Cameron, senior botanic officer, Mt Cootha Botanical Gardens, Brisbane, Australia. Leaf samples were dried in a Sunbeam food dehydrator and stored at -30 o C. Prior to use, the leaves were freshly ground to a coarse powder and 1 g quantities were weighed into separate tubes. A volume of 50 mL methanol (Ajax, Australia; AR grade) or sterile deionised water were added to individual tubes and extracted for 24 hrs at 4 o C with gentle shaking. The extracts was filtered through filter paper (Whatman No. 54) under vacuum, followed by drying by rotary evaporation in an Eppendorf concentrator 5301. The resultant pellets were dissolved in 10 mL sterile deionised water (containing 1% DMSO). The extracts were passed through 0.22 µm filter (Sarstedt) and stored at 4 o C until use.
Qualitative phytochemical studies
Phytochemical analysis of the B. myrtifolia and S. anisatum leaf extracts for the presence of saponins, phenolic compounds, flavonoids, phytosteroids, triterpenoids, cardiac glycosides, anthraquinones, tannins and alkaloids was conducted by previously described assays. [20] [21] Antibacterial screening Test microorganisms 
Evaluation of antimicrobial activity
Antimicrobial activity of all plant extracts was determined using a modified disc diffusion assay. [22] [23] [24] Briefly, 100 µL of each bacterial culture was grown in 10 mL of fresh nutrient broth until they reached a count of ~10 8 cells/mL. A volume of 100 µL of the bacterial suspension was spread onto nutrient agar plates and extracts were tested for antibacterial activity using 5 mm sterilised filter paper discs. Discs were infused with 10 µL of the plant extracts, allowed to dry and placed onto the inoculated plates. The plates were allowed to stand at 4°C for 2 h before incubation at 30°C for 24 h. The diameters of the inhibition zones were measured to the closest whole millimetre. Each assay was performed in at least triplicate. Mean values (± SEM) are reported in this study. Standard discs of ampicillin (10 µg) were obtained from Oxoid, Australia and were used as positive controls to compare antibacterial activity. Filter discs infused with 10 µL of distilled water were used as a negative control.
Minimum inhibitory concentration (MIC) determination
The minimum inhibitory concentration (MIC) of each extract against susceptible bacteria was determined as previously described. 25, 26 Briefly, the plant extracts were diluted in deionised water and tested across a range of concentrations. Discs were infused with 10 µL of the test dilutions, allowed to dry and placed onto inoculated plates. The assay was completed as outlined above and graphs of the zone of inhibition versus concentration were plotted for each extract. Linear regression was used to determine the MIC values of each extract.
Bacterial growth time course assay
Bacterial growth time course studies were performed as previously described. 27 Briefly, 3 mL of the ATCC reference bacterial cultures (Klebsiella pneumoniae (ATCC31488), Escherichia coli (ATCC 25922) and Proteus mirabilis (ATCC21721)) in nutrient broth were added to 27 mL nutrient broth containing 3 mL of 10 mg/mL methanolic plant extract to give a final concentration of 1000 µg/mL in the assay. The tubes were incubated at 30 o C with gentle shaking. The optical density was measured hourly at 550 nm for a 6 h incubation period. Control tubes were incubated under the same conditions but without the extract. All assays were performed in triplicate.
Toxicity screening Reference toxin for toxicity screening
Potassium dichromate (K 2 Cr 2 O 7 ) (AR grade, Chem-Supply, Australia) was prepared as a 4 mg/mL solution in distilled water and was serially diluted in artificial seawater for use in the Artemia franciscana nauplii bioassay.
Artemia franciscana nauplii toxicity screening
Toxicity was tested using an adapted Artemia franciscana nauplii lethality assay. [28] [29] [30] Briefly, 400 µL of seawater containing approximately 46 (mean 46.2, n=125, SD 12.5) A. franciscana nauplii were added to wells of a 48 well plate and immediately used for bioassay. A volume of 400 µL of diluted plant extracts or the reference toxin were transferred to the wells and incubated at 25 ± 1 o C under artificial light (1000 Lux). A 400 µL seawater negative control was run in triplicate for each plate. All treatments were performed in at least triplicate. The wells were checked at regular intervals and the number of dead counted. The nauplii were considered dead if no movement of the appendages was detected within 10 seconds. After 24 h, all nauplii were sacrificed and counted to determine the total % mortality per well. The LC 50 with 95% confidence limits for each treatment was determined using probit analysis.
Statistical analysis
Data are expressed as the mean ± SEM of at least three independent experiments. One way ANOVA was used to calculate statistical significance between control and treated groups with a P value < 0.01 considered to be statistically significant.
RESULTS
Liquid extraction yields and qualitative phytochemical screening
Extraction of 1 g of B. myrtifolia and S. anisatum leaves with methanol or deionised water yielded dried extracts ranging from 118 mg (aqueous S. anisatum extract) to 253 mg (methanolic B. myrtifolia extract) ( Table 1) . Higher extraction yields were determined for both the B. myrtifolia extracts than for the corresponding S. anisatum extracts. The dried extracts were resuspended in 10 mL of deionised water (containing 1% DMSO), resulting in the extract concentrations shown in Table 1 . Qualitative phytochemical studies showed that all solvents extracted similar classes of phytochemicals. All had high levels of phenolics (high levels of water soluble phenolics, moderate levels of water insoluble phenolics). Generally, all extracts also contained moderate levels of triterpenoids and tannins, as well as low levels of flavonoids. All extracts were generally devoid of all other classes of phytochemicals.
Antimicrobial activity
To determine the growth inhibitory activity of the B. myrtifolia and S. anisatum extracts against the panel of pathogenic bacteria, aliquots (10 µL) of each extract were screened in the disc diffusion assay. Aqueous and methanolic B. myrtifolia extracts inhibited a broad spectrum of the bacterial species screened (Figure 2 ). The methanolic B. myrtifolia extract was a more potent growth inhibitor than the aqueous extract against most bacterial species (as assessed by the sizes of the zones of inhibition). Noteably, the opposite trend was noted for P. mirabilis growth inhibition, with the aqueous extracts inhibiting the reference and clinical strains by 10.3 ± 0.6 and 11.3 ± 0.6 mm respectively. This inhibition was particularly noteworthy compared to the inhibition by the ampicillin control (10 µg: inhibition zones of approximately 10 mm) In contrast, the methanolic B. myrtifolia extract inhibited P. mirabilis growth by 8.5 ± 0.6 mm (reference strain) and 8.6 ± 0.6 mm (clinical isolate strain). Similar bacterial growth inhibitory trends were noted for the S. anisatum extracts ( Figure 3 ). As reported for the B. myrtifolia extracts, P. mirabilis was more susceptible to growth inhibition by the S. anisatum extracts than were the other bacterial species screened. Indeed, inhibition zones of 11.7 ± 0.5 mm and 12.3 ± 0.6 mm were measured for the inhibition of the aqueous extract against the reference and clinical isolate strains of P. mirabilis respectively. The antimicrobial efficacy was further quantified by determining the MIC values for each extract against the microbial species which were determined to be susceptible. The methanolic and aqueous extracts of both species were potent growth inhibitors of several bacterial species (as judged by MIC; Table 2 ). P. mirabilis was the most susceptible bacteria to the B. myrtifolia and S. anisatum extracts, with MIC values generally <1000 µg/mL (<10 µg infused into the disc). The aqueous extracts of both species were particularly potent P. mirabilis growth inhibitors. MIC values of 307 and 125 µg/mL were determined for aqueous B. myrtifolia extract against the reference and clinical strains of the bacterium respectively. The aqueous S. anisatum extract was a similarly potent growth inhibitor, with MIC values of 289 (reference P. mirabilis strain) and 105 µg/mL (clinical isolate P. mirabilis strain). The methanolic extracts were also potent P. mirabilis growth inhibitors, albeit with slightly higher MIC values (in the 600-1200 µg/mL range). As P. mirabilis infection is a common cause of urinary tract infections and has also been identified as a trigger of rheumatoid arthritis, 31 
Bacterial growth time course assay
The antibacterial activity of the B. myrtifolia and S. anisatum extracts was further investigated in the reference bacterial strains by bacterial growth time course assays in the presence and absence of the extract. As the methanolic extracts were generally more potent than the aqueous extracts (except for P. mirabilis inhibition where aqueous extracts were more potent), only the effect of the methanolic extracts on bacterial growth time course was examined. The starting concentration of the extract used in these assays was 1000 µg/mL. Methanolic extracts of both B. myrtifolia and S. anisatum significantly inhibited E. coli (Figure 4a ), K. pneumoniae ( Figure 4b ) and P. mirabilis (Figure 4c ) growth within 1 h, indicating a rapid antimicrobial action. Whilst E. coli and K. pneumoniae growth was inhibited for at least the first 4 hours of the time course, these bacteria were generally able to overcome this inhibition by 6 h, with the recorded turbidity not significantly different to that of the untreated control. This indicates that the growth inhibition of these bacteria was bacteriostatic for the methanolic B. myrtifolia and S. anisatum extracts at the concentrations tested. In contrast, inhibition of P. mirabilis by the methanolic B. myrtifolia and S. anisatum extracts was substantially more profound, with growth still significantly inhibited by the end of the 6 h time course study. This may indicate that these extracts have bactericidal activity against P. mirabilis at the dose tested.
Quantification of toxicity
The toxicity of the B. myrtifolia and S. anisatum extracts was initially tested in the Artemia franciscana nauplii bioassay at a concentration of 2000 µg/mL ( Figure 5 ). All extracts induced low levels of mortality at 24 and 48 h, similar to the % mortality seen for the seawater control.
As none of the extracts induced toxicity significantly different from the seawater control, all were deemed to be nontoxic. In contrast, the potassium dichromate positive controls induced mortality within 4 h (results not shown), with 100 % mortality induction seen by 24 h. To further quantify the effect of toxin concentration on the induction of mortality, the extracts were serially diluted in artificial seawater to test across a range of concentrations in the Artemia nauplii bioassay (Table 3) . For comparison, serial dilutions of potassium dichromate were also tested. All B. myrtifolia and S. anisatum extracts were determined to be nontoxic, with LC 50 values substantially greater than 1000 µg/mL following 24 h exposure. Extracts with an LC 50 of greater than 1000 µg/mL towards Artemia nauplii have previously been defined as being nontoxic. 29
DISCUSSION
Plant derived remedies are becoming increasingly sought after in the treatment of a myriad of diseases and disorders due both to their perception of greater safety than synthetic drugs, and the failure of current drug regimens to effectively treat many diseases. This current study reports on the growth inhibitory properties of B. myrtifolia and S. anisatum leaf extracts against a panel of pathogenic bacteria, and on their toxicity. The gram positive and gram negative bacteria tested in this study demonstrated similar susceptibilities towards the B. myrtifolia and S. anisatum extracts, albeit with a slightly higher susceptibility for the gram negative bacteria. Many previous studies with other plant species report a greater susceptibility towards solvent extracts for South American, 33 African 34 and Australian plant extracts. 35, 36 Our study examined the ability of B. myrtifolia and S. anisatum extracts to inhibit the growth of a panel of medicinally important bacterial pathogens. The aqueous extracts of both species were identified as being particularly potent inhibitors of P. mirabilis. MIC values against the clinical P. mirabilis isolate strain of 125 and 105 µg/mL were determined for the aqueous B. myrtifolia and S. anisatum extracts respectively. As P. mirabilis can trigger rheumatoid arthritis in genetically susceptible individuals 31, 32 these extracts have potential for the development of rheumatoid arthritis inhibitory therapies. The methanolic S. anisatum extract also displayed moderate K. pneumoniae growth inhibitory properties (MIC values < 5000 µg/mL for both the reference and clinical strains). As K. pneumoniae can trigger ankylosing spondylitis in genetically susceptible individuals 37, 38 this extract may also be useful in the prevention of ankylosing spondylitis. Furthermore, the methanolic S. anisatum extract was a good inhibitor of S. pyogenes growth. S. pyogenes may cause a myriad of diseases including streptococcal pharyngitis, impetigo and rheumatic heart disease, depending on which tissue it infects. 39, 40 Thus, the methanolic S. anisatum extract may be useful in the prevention of these diseases. Aside from inhibition of the bacterial triggers of the autoimmune disease discussed above, the B. myrtifolia and S. anisatum extracts also were moderate to good inhibitors of several other bacterial pathogens. Both the aqueous and methanolic S. anisatum extracts inhibited E. coli growth. However, the methanolic extract displayed the greater efficacy, with MICs of 893 and 1255 µg/mL against the reference and clinical isolate strains respectively. Thus, this extract has potential in the treatment of diarrhoea and dysentery caused by enteric E. coli infections, as well as urinary tract E. coli infections. The aqueous and methanolic B. myrtifolia extracts were also moderate to good inhibitors of S. aureus and S. epidermidis growth (MICs 1750-2750 µg/mL). As both of these bacteria are skin disease pathogens, the B. myrtifolia extracts also may have applications as topical treatments of these diseases. Whilst an investigation of the phytochemistry of the B. myrtifolia and S. anisatum extracts was beyond the scope of our study, other plants of the family Myrtaceae are well known for their high terpenoid contents. In particular, high monoterpenoid contents have been reported for many Myrtaceae spp. 1 Monoterpenes have been reported to exert a wide variety of biological effects including antibacterial, antifungal, anti-inflammatory and anti-tumour activities 16 and therefore may contribute to the bacterial growth inhibitory activity of the B. myrtifolia and S. anisatum extracts reported here. A wide variety of monoterpenoids including camphor, carvone, cineole, borneol, menthone, pinene, terpinene, as well as their derivatives, inhibit the growth of an extensive panel of pathogenic and food spoilage bacteria. 41 Interestingly, several of these monoterpenoids have also been reported to suppress NF-κB signaling (the major regulator of inflammatory diseases). [42] [43] [44] [45] This may be particularly relevant for the extracts which inhibited P. mirabilis (a bacterial trigger of rheumatoid arthritis) 31, 32 and K. pneumoniae (a trigger of ankylosing spondylitis). 37, 38 The terpene components in these extracts may have a pleuripotent mechanism in blocking the autoimmune inflammatory diseases and relieving its symptoms by acting on both the initiator and downstream inflammatory stages of the disease. Further phytochemical evaluation studies and bioactivity driven isolation of active components is required to further evaluate the mechanism(s) of bacterial growth inhibition. Another commonality between the inhibitory B. myrtifolia and S. anisatum extracts was that all contained moderate levels of tannins. Many studies have reported potent growth inhibitory activities for a number of tannin compounds. Gallotannins have been reported to inhibit the growth of a broad spectrum of bacterial species 46 through a variety of mechanisms including binding cell surface molecules including lipotoichoic acid and proline-rich cell surface proteins, 47, 48 and by inhibiting glucosyltransferase enzymes. 49 Elligitannins are also highly potent inhibitors of bacterial growth, with MIC values as low as 62.5 µg/mL. 46, 48 Ellagitannins have also been reported to function via several antibiotic mechanisms including interaction with cytoplasmic oxidoreductases and by disrupting bacterial cell walls. 46, 48 Thus, it is likely that multiple compounds within the B. myrtifolia and S. anisatum extracts may contribute to the inhibition of S. pyogenes growth.
The findings reported here also demonstrate that all of the B. myrtifolia and S. anisatum extracts were nontoxic towards Artemia franciscana nauplii, with LC 50 values substantially > 1000 µg/mL. Extracts with LC 50 values > 1000 µg/mL towards Artemia nauplii are defined as being nontoxic. 29 Whilst our preliminary toxicity studies indicate that these extracts may be safe for therapeutic use, studies using human cell lines are required to further evaluate the safety of these extracts. Furthermore, whilst these studies have demonstrated the potential of the B. myrtifolia and S. anisatum extracts in the development of future antibiotic chemotherapeutics for the prevention and treatment of urinary tract infections, autoimmune diseases (particularly rheumatoid arthritis and ankylosing spondylitis) and some skin diseases, more work is required to isolate the inhibitory components and determine the mechanism of inhibition.
CONCLUSION
The results of this study demonstrate the potential of the B. myrtifolia and S. anisatum extracts as inhibitors of pathogenic bacteria growth. Furthermore, their lack of toxicity indicates than they are safe for internal as well as topical treatment. Further studies aimed at the purification and identification of bioactive components are needed to examine the mechanisms of action of these agents.
